|
1
|
Gill SE and Parks WC: Metalloproteinases
and their inhibitors: regulators of wound healing. Int J Biochem
Cell Biol. 40:1334–1347. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang C, Zhu P, Yan L, et al: Dynamic
changes in matrix metalloproteinase 9 and tissue inhibitor of
metalloproteinase 1 levels during wound healing in diabetic rats. J
Am Podiatr Med Assoc. 99:489–496. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reiss MJ, Han YP, Garcia E, et al: Matrix
metalloproteinase-9 delays wound healing in a murine wound model.
Surgery. 147:295–302. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu Y, Min D, Bolton T, et al: Increased
matrix metalloproteinase-9 predicts poor wound healing in diabetic
foot ulcers. Diabetes Care. 32:117–119. 2009. View Article : Google Scholar
|
|
5
|
Rayment EA, Upton Z and Shooter GK:
Increased matrix metalloproteinase-9 (MMP-9) activity observed in
chronic wound fluid is related to the clinical severity of the
ulcer. Br J Dermatol. 158:951–961. 2008. View Article : Google Scholar
|
|
6
|
Bell DS: Beta-cell rejuvenation with
thiazolidinediones. Am J Med. 115:20S–23S. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saitoh Y, Chun-ping C, Noma K, Ueno H,
Mizuta M and Nakazato M: Pioglitazone attenuates fatty acid-induced
oxidative stress and apoptosis in pancreatic beta cells. Diabetes
Obes Metab. 10:564–573. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu X, Luo D, Zheng M, Hao Y, Hou L and
Zhang S: Effect of pioglitazone on insulin resistance in
fructose-drinking rats correlates with AGEs/RAGE inhibition and
block of NADPH oxidase and NF kappa B activation. Eur J Pharmacol.
629:153–158. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ao C, Huo Y, Qi L, Xiong Z, Xue L and Qi
Y: Pioglitazone suppresses the lipopolysaccharide-induced
production of inflammatory factors in mouse macrophages by
inactivating NF-kappaB. Cell Biol Int. 34:723–730. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wan H, Yuan Y, Qian A, Sun Y and Qiao M:
Pioglitazone, a PPARgamma ligand, suppresses NFkappaB activation
through inhibition of IkappaB kinase activation in cerulein-treated
AR42J cells. Biomed Pharmacother. 62:466–472. 2008. View Article : Google Scholar
|
|
11
|
Bell DS: Beneficial effects resulting from
thiazolidinediones for treatment of type 2 diabetes mellitus.
Postgrad Med. 8:35–44. 2003.PubMed/NCBI
|
|
12
|
Gumieniczek A, Hopkała H and Zabek A:
Protective effects of a PPARgamma agonist pioglitazone on
anti-oxidative system in testis of diabetic rabbits. Pharmazie.
63:377–378. 2008.PubMed/NCBI
|
|
13
|
Collino M, Aragno M, Mastrocola R, et al:
Modulation of the oxidative stress and inflammatory response by
PPAR-gamma agonists in the hippocampus of rats exposed to cerebral
ischemia/reperfusion. Eur J Pharmacol. 530:70–80. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gumieniczek A, Krzywdzińska M and Nowak M:
Modulation of nitrosative/oxidative stress in the lung of
hyperglycemic rabbits by two antidiabetics, pioglitazone and
repaglinide. Exp Lung Res. 35:371–379. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Somi MH, Hajipour B, Asl NA, et al:
Pioglitazone attenuates ischemia/reperfusion-induced liver injury
in rats. Transplant Proc. 41:4105–4109. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bernardo A, Bianchi D, Magnaghi V and
Minghetti L: Peroxisome proliferator-activated receptor-gamma
agonists promote differentiation and antioxidant defenses of
oligodendrocyte progenitor cells. J Neuropathol Exp Neurol.
68:797–808. 2009. View Article : Google Scholar
|
|
17
|
Fukami K, Yamagishi SI, Sakai K, Kaida Y,
Adachi T, Ando R and Okuda S: Potential inhibitory effects of
L-carnitine supplementation on tissue advanced glycation end
products in patients with hemodialysis. Rejuvenation Res.
16:460–466. 2013. View Article : Google Scholar
|
|
18
|
Goldin A, Beckman JA, Schmidt AM and
Creager MA: Advanced glycation end products: sparking the
development of diabetic vascular injury. Circulation. 114:597–605.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bierhaus A and Nawroth PP: Multiple levels
of regulation determine the role of the receptor for AGE (RAGE) as
common soil in inflammation, immune responses and diabetes mellitus
and its complications. Diabetologia. 52:2251–2263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wautier JL and Guillausseau PJ: Advanced
glycation end products, their receptors and diabetic angiopathy.
Diabetes Metab. 27:535–542. 2001.PubMed/NCBI
|
|
21
|
Yonutas HM and Sullivan PG: Targeting PPAR
isoforms following CNS injury. Curr Drug Targets. 14:733–742. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pan HW, Xu JT and Chen JS: Pioglitazone
inhibits TGFβ induced keratocyte transformation to myofibroblast
and extracellular matrix production. Mol Biol Rep. 38:4501–4508.
2011.
|
|
23
|
Dong X, Geng Z, Zhao Y, Chen J and Cen Y:
Involvement of mast cell chymase in burn wound healing in hamsters.
Exp Ther Med. 5:643–647. 2013.PubMed/NCBI
|
|
24
|
Da Silva Morais A, Abarca-Quinones J,
Horsmans Y, Stärkel P and Leclercq IA: Peroxisome
proliferated-activated receptor gamma ligand, Pioglitazone, does
not prevent hepatic fibrosis in mice. Int J Mol Med. 19:105–112.
2007.PubMed/NCBI
|
|
25
|
Lahiri S, Sen T and Palit G: Involvement
of glucocorticoid receptor and peroxisome proliferator activated
receptor-gamma in pioglitazone mediated chronic gastric ulcer
healing in rats. Eur J Pharmacol. 609:118–125. 2009. View Article : Google Scholar
|
